Psychiatry and Neurology, Neurology · Spokane, WA
NPI
1003969684
Since 2007
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
610 S Sherman St, Suite 201
Spokane, WA, 99202
Phone (509) 458-7720
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.4M
87,760 services
Medicare patients, 2024
821
Average age 74
Drug cost, 2024
$3.3M
5,006 prescriptions
Company payments, 2025
$212K
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jason L Aldred was code J0588 (injection, incobotulinumtoxin a, 1 unit), 42,910 times for 68 patients. In total Jason L Aldred billed 87,760 services in 76 codes, and Medicare paid $2.4M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-06-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0588 Injection, incobotulinumtoxin a, 1 unit | Office | 42,910 | 68 | $4.10 | $176K |
| J0586 Injection, abobotulinumtoxina, 5 units | Office | 8,800 | 18 | $6.75 | $59K |
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 4,300 | 12 | $4.87 | $21K |
| J0587 Injection, rimabotulinumtoxinb, 100 units | Office | 1,585 | 18 | $10.16 | $16K |
| 99214 Office E&M - Established | Office | 1,064 | 503 | $97.52 | $104K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,021 | 489 | $12.81 | $13K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 561 | 102 | $49.68 | $28K |
| 99215 Office E&M - Established | Office | 372 | 216 | $136.57 | $51K |
| 95886 Electrical Nerve Conductivity | Office | 350 | 192 | $80.24 | $28K |
| 95983 Electrical Nerve Conductivity | Office | 308 | 114 | $37.96 | $12K |
| 95874 Musculoskeletal | Office | 203 | 69 | $64.47 | $13K |
| 95984 Electrical Nerve Conductivity | Office | 141 | 48 | $34.46 | $4,860 |
| 76536 Ultrasound - Nonspecific | Office | 134 | 40 | $92.15 | $12K |
| 64616 Musculoskeletal | Office | 134 | 40 | $141.44 | $19K |
| 99205 Office E&M - New | Office | 115 | 115 | $169.30 | $19K |
By year: 2022 $2.6M for 95,987 services; 2023 $1.9M for 86,720 services; 2024 $2.4M for 87,760 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jason L Aldred prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 911 prescriptions and refills. In total Jason L Aldred wrote 5,006 Medicare prescriptions that cost $3.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 911 | 2,181 | 250 | $35K |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 627 | 1,466 | 168 | $42K |
| Clonazepam Generic | 228 | 298 | 38 | $2,214 |
| Rytary Carbidopa/Levodopa | 207 | 316 | 39 | $272K |
| Amantadine Amantadine Hcl | 194 | 376 | 48 | $15K |
| Rasagiline Mesylate Generic | 186 | 444 | 46 | $34K |
| Primidone Generic | 185 | 405 | 44 | $5,252 |
| Rivastigmine Rivastigmine Tartrate | 167 | 293 | 41 | $12K |
| Gabapentin Generic | 149 | 250 | 36 | $2,391 |
| Pramipexole Dihydrochloride Pramipexole Di-Hcl | 144 | 290 | 38 | $3,689 |
| Entacapone Generic | 144 | 249 | 42 | $20K |
| Nuplazid Pimavanserin Tartrate | 110 | 124 | 14 | $598K |
| Quetiapine Fumarate Generic | 97 | 126 | 22 | $1,983 |
| Donepezil Hcl Generic | 82 | 159 | 18 | $755 |
| Ropinirole Hcl Generic | 73 | 156 | 18 | $2,695 |
Brand drugs: 804 claims; generic drugs: 4,202 claims; opioid claims: 27.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jason L Aldred $212K ($212K in general payments such as food, travel and fees) from 21 companies. The largest payer was Teva Pharmaceuticals USA, Inc. with $115K.
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. TEVA | 81 | $115K |
| Abbvie Inc. ABBV | 53 | $78K |
| Amneal Pharmaceuticals LLC AMRX | 13 | $7,840 |
| Boston Scientific Corporation BSX | 28 | $6,772 |
| MDD US Operations, LLC | 4 | $2,506 |
| Merz Pharmaceuticals, LLC | 7 | $344 |
| Neurocrine BioSciences, Inc. NBIX | 11 | $246 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 7 | $166 |
| Biogen, Inc. BIIB | 2 | $137 |
| ACADIA Pharmaceuticals Inc ACAD | 3 | $95.33 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.